JP4754216B2 - ｄｓＲＮＡ投与による神経疾患の処置 - Google Patents

ｄｓＲＮＡ投与による神経疾患の処置 Download PDF

Info

Publication number
JP4754216B2
JP4754216B2 JP2004533463A JP2004533463A JP4754216B2 JP 4754216 B2 JP4754216 B2 JP 4754216B2 JP 2004533463 A JP2004533463 A JP 2004533463A JP 2004533463 A JP2004533463 A JP 2004533463A JP 4754216 B2 JP4754216 B2 JP 4754216B2
Authority
JP
Japan
Prior art keywords
pain
dsrna
strand
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004533463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501256A5 (https=
JP2006501256A (ja
Inventor
ガブリエレ・ドルン
パムポッシュ・ガンジュ
ジョナサン・ホール
マリア・ヴァンダ・ヘンミングス
ヴィリアム・レオナルト・ヴィスハルト
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2006501256A publication Critical patent/JP2006501256A/ja
Publication of JP2006501256A5 publication Critical patent/JP2006501256A5/ja
Application granted granted Critical
Publication of JP4754216B2 publication Critical patent/JP4754216B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004533463A 2002-09-04 2003-09-03 ｄｓＲＮＡ投与による神経疾患の処置 Expired - Lifetime JP4754216B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40800002P 2002-09-04 2002-09-04
US60/408,000 2002-09-04
US45797103P 2003-03-27 2003-03-27
US60/457,971 2003-03-27
PCT/EP2003/009787 WO2004022075A1 (en) 2002-09-04 2003-09-03 Treatment of neurological disorders by dsrna adminitration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011034713A Division JP2011178783A (ja) 2002-09-04 2011-02-21 ｄｓＲＮＡ投与による神経疾患の処置

Publications (3)

Publication Number Publication Date
JP2006501256A JP2006501256A (ja) 2006-01-12
JP2006501256A5 JP2006501256A5 (https=) 2006-10-19
JP4754216B2 true JP4754216B2 (ja) 2011-08-24

Family

ID=31981555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004533463A Expired - Lifetime JP4754216B2 (ja) 2002-09-04 2003-09-03 ｄｓＲＮＡ投与による神経疾患の処置
JP2011034713A Pending JP2011178783A (ja) 2002-09-04 2011-02-21 ｄｓＲＮＡ投与による神経疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011034713A Pending JP2011178783A (ja) 2002-09-04 2011-02-21 ｄｓＲＮＡ投与による神経疾患の処置

Country Status (5)

Country Link
US (3) US20060030534A1 (https=)
EP (1) EP1551424B1 (https=)
JP (2) JP4754216B2 (https=)
AU (1) AU2003260489A1 (https=)
WO (1) WO2004022075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
EP1407787B1 (en) * 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Method of promoting nucleic acid transfer
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
MX2007002423A (es) * 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
AR051829A1 (es) * 2004-10-27 2007-02-14 Schering Corp Composiciones y metodos para inhibicion de nav 1 mediante arn corto de interferencia
WO2007020935A1 (ja) * 2005-08-17 2007-02-22 Ono Pharmaceutical Co., Ltd. Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
RU2607033C2 (ru) * 2010-09-28 2017-01-10 Ноно Инк. Пептиды nd2 и способы лечения неврологического заболевания
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
US12128062B2 (en) 2018-08-14 2024-10-29 University Of Maryland, Baltimore Methods for targeting pain directed at metabolic pathways

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504011A (ja) * 1995-04-18 1999-04-06 イナファーマ，インコーポレイテッド 疼痛の治療方法
JP2002507191A (ja) * 1997-04-28 2002-03-05 サイトセラピューティクス，インコーポレイテッド 痛覚脱失の生成または神経保護のためのコナントキンの使用
JP2005536438A (ja) * 2001-06-08 2005-12-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 過分極活性化型環状ヌクレオチド依存性チャンネルに標的を定めることによる疼痛の治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
US5155689A (en) * 1991-01-17 1992-10-13 By-Word Technologies, Inc. Vehicle locating and communicating method and apparatus
US5214281A (en) * 1992-03-20 1993-05-25 Rowe Douglas J Method for locating sub-terranean geological aggregate deposits
US5724243A (en) * 1995-02-10 1998-03-03 Highwaymaster Communications, Inc. Method and apparatus for determining expected time of arrival
JP3371605B2 (ja) * 1995-04-19 2003-01-27 日産自動車株式会社 大気効果表示機能付き鳥瞰図表示ナビゲーションシステム
US5751450A (en) * 1996-05-22 1998-05-12 Medar, Inc. Method and system for measuring color difference
US6990458B2 (en) * 1997-08-28 2006-01-24 Csg Systems, Inc. System and method for computer-aided technician dispatch and communication
US6119124A (en) 1998-03-26 2000-09-12 Digital Equipment Corporation Method for clustering closely resembling data objects
US6240409B1 (en) 1998-07-31 2001-05-29 The Regents Of The University Of California Method and apparatus for detecting and summarizing document similarity within large document sets
DE69910140T2 (de) 1998-10-08 2004-06-03 Novartis Ag Verfahren zur Sulfurierung von Phosphor-enthaltenden Verbindungen
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7415313B2 (en) * 2000-07-07 2008-08-19 New Vectors Llc Spatial coordination system
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US6658423B1 (en) 2001-01-24 2003-12-02 Google, Inc. Detecting duplicate and near-duplicate files
WO2002067858A2 (en) * 2001-02-22 2002-09-06 University Of Maryland, Baltimore Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms
US6845394B2 (en) * 2001-04-16 2005-01-18 Sun Microsystems, Inc. Software delivery method with enhanced batch redistribution for use in a distributed computer network
US20030008048A1 (en) 2001-06-08 2003-01-09 David Winston Methods and compositions for helping the body resist the effects of the aging process
WO2003082255A2 (en) * 2002-04-03 2003-10-09 Novartis Ag Use of mob-5 in pain
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
EP1592412A1 (en) * 2003-01-31 2005-11-09 Novartis AG Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
US20050132197A1 (en) 2003-05-15 2005-06-16 Art Medlar Method and apparatus for a character-based comparison of documents
US20070085716A1 (en) 2005-09-30 2007-04-19 International Business Machines Corporation System and method for detecting matches of small edit distance
US7499869B2 (en) * 2006-02-02 2009-03-03 Matthew Iknoian System and method for scheduling employee shifts
US7562186B2 (en) 2006-04-11 2009-07-14 Data Domain, Inc. Efficient data storage using resemblance of data segments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504011A (ja) * 1995-04-18 1999-04-06 イナファーマ，インコーポレイテッド 疼痛の治療方法
JP2002507191A (ja) * 1997-04-28 2002-03-05 サイトセラピューティクス，インコーポレイテッド 痛覚脱失の生成または神経保護のためのコナントキンの使用
JP2005536438A (ja) * 2001-06-08 2005-12-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 過分極活性化型環状ヌクレオチド依存性チャンネルに標的を定めることによる疼痛の治療

Also Published As

Publication number Publication date
WO2004022075A1 (en) 2004-03-18
AU2003260489A1 (en) 2004-03-29
EP1551424A1 (en) 2005-07-13
US20120053230A1 (en) 2012-03-01
US8129354B2 (en) 2012-03-06
US20060030534A1 (en) 2006-02-09
JP2006501256A (ja) 2006-01-12
US8198259B2 (en) 2012-06-12
JP2011178783A (ja) 2011-09-15
EP1551424B1 (en) 2015-07-01
US20080153768A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
JP2011178783A (ja) ｄｓＲＮＡ投与による神経疾患の処置
CN102666856B (zh) 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
JP7058656B2 (ja) トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物を用いてＴＴＲ関連疾患を治療または予防するための方法
DE60310944T2 (de) Neue formen von interferierenden rns-molekülen
JP6894230B2 (ja) 脳由来神経栄養因子（ｂｄｎｆ）関連疾病の、ｂｄｎｆに対する天然アンチセンス転写物の抑制による治療
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
KR20220024153A (ko) 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
JP2011015695A (ja) Ｎａｖ１．８の短い干渉核酸阻害のための組成物および方法
KR20100017422A (ko) 작은 간섭 ＲＮＡ(ｓｉＲＮＡ)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법
JP6008845B2 (ja) 眼の状態の治療および／または予防のための方法および組成物におけるｓｉＲＮＡおよびそれらの使用
KR20180104075A (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
KR20150047513A (ko) 눈 증상의 치료 및/또는 예방을 위한 방법 및 조성물에서 sirna 및 이들의 용도
WO2003057843A2 (en) Methods and materials for modulating trpc4
CN101808647A (zh) 通过抑制Gpr12治疗认知障碍的方法
WO2005083083A2 (en) Materials and methods for treatment of allergic disease
EP1478655A2 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
EP2851426B1 (en) Compositions and methods for inhibiting expression of RRM2 genes
CN120574835B (zh) 一种靶向rankl基因的小核酸及其在治疗骨科疾病中的应用
Bristol et al. [35] Use of antisense oligodeoxynucleotides to inhibit expression of glutamate transporter subtypes
WO2025213093A1 (en) Antisense oligonucleotides for treating pitt hopkin syndrome
WO2011105902A2 (en) Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) Antagonists of complement component 9 (c9) and uses thereof
US20080027015A1 (en) Methods and Materials for Modulating Enac-Beta
EA048423B1 (ru) РНКи-АГЕНТЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (APOC3)
CA2534996A1 (en) The use of sirna silencing in the prevention of metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110510

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110525

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140603

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4754216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term